R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of lenalidomide combined with rituximab, vincristine,
doxorubicin, cyclophosphamide, and prednisone (r2-chop) in the initial treatment of
DEL-DLBCL. The primary endpoint is the complete response rate, and the second endpoints are
survival time (OS and PFS) and overall response rate.